JP2004533421A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533421A5
JP2004533421A5 JP2002574998A JP2002574998A JP2004533421A5 JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5 JP 2002574998 A JP2002574998 A JP 2002574998A JP 2002574998 A JP2002574998 A JP 2002574998A JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5
Authority
JP
Japan
Prior art keywords
monolipopeptide
peptide
composition according
amino acids
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002574998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/002188 external-priority patent/WO2002076485A2/en
Publication of JP2004533421A publication Critical patent/JP2004533421A/ja
Publication of JP2004533421A5 publication Critical patent/JP2004533421A5/ja
Withdrawn legal-status Critical Current

Links

JP2002574998A 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン Withdrawn JP2004533421A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27869801P 2001-03-27 2001-03-27
PCT/IB2002/002188 WO2002076485A2 (en) 2001-03-27 2002-03-27 Vaccine for modulating between t1 and t2 immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010255171A Division JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Publications (2)

Publication Number Publication Date
JP2004533421A JP2004533421A (ja) 2004-11-04
JP2004533421A5 true JP2004533421A5 (https=) 2005-12-22

Family

ID=23065998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002574998A Withdrawn JP2004533421A (ja) 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Country Status (9)

Country Link
US (3) US8198400B2 (https=)
EP (1) EP1377275B1 (https=)
JP (2) JP2004533421A (https=)
AT (1) ATE343375T1 (https=)
AU (1) AU2002309141B2 (https=)
CA (1) CA2441809C (https=)
DE (1) DE60215627T2 (https=)
ES (1) ES2424131T3 (https=)
WO (1) WO2002076485A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
WO2003089574A2 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
EP1677773A1 (en) * 2003-10-14 2006-07-12 Biomira, Inc. Combination therapy for cancer
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PL1896051T3 (pl) * 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US8703180B1 (en) * 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
SG2014014021A (en) * 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
KR20140023903A (ko) 2011-02-24 2014-02-27 온코타이레온, 인코포레이티드 항원보강제를 갖는 muc1 기초 당지질펩티드 백신
WO2015104656A1 (en) 2014-01-07 2015-07-16 Babita Agrawal Immunomodulatory compositions and methods of use thereof
EP4480544A3 (en) 2015-08-25 2025-03-26 Babita Agrawal Immunomodulatory compositions andmethods of use thereof
WO2018156106A1 (en) * 2017-02-22 2018-08-30 Ding Enyu An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
EP0203676B1 (en) 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
WO1995027505A1 (en) 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU734253B2 (en) 1996-03-20 2001-06-07 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
ATE273320T1 (de) 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
ES2357960T3 (es) 1997-05-08 2011-05-04 Oncothyreon Inc. Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Muc−1由来のペプチド
ES2370262T3 (es) 1999-11-15 2011-12-14 Oncothyreon Inc. Análogos del lípido a sintéticos y sus utilizaciones.
WO2001070265A2 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
WO2003089574A2 (en) 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
US7820627B2 (en) 2002-05-09 2010-10-26 Oncothyreon Inc. Lipid A and other carbohydrate ligand analogs
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PL1896051T3 (pl) 2005-06-28 2015-04-30 Oncothyreon Inc Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1)

Similar Documents

Publication Publication Date Title
JP2004533421A5 (https=)
Felnerova et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
JP2828391B2 (ja) オリゴ糖を表面に有するリポソーム
AU2002311616B2 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
Arunagirinathan et al. Self-assembled surfactant nano-structures important in drug delivery: a review
EP2040745B1 (en) Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
JP6016970B2 (ja) インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
JP5519477B2 (ja) T1免疫応答とt2免疫応答との間で調節するためのワクチン
US5576017A (en) Heterovesicular liposomes
US9757428B2 (en) Designed peptides for tight junction barrier modulation
JPH05503521A (ja) 指状突起―融合リポソームおよびゲル
US20050058697A1 (en) Cell penetrating therapeutic agents
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
KR20170016315A (ko) 알루미늄 염-흡착 백신의 면역자극 효력의 증진 방법
CA2802443C (en) Vaccine compositions based on sticholysin encapsulated in liposomes
Bally et al. Novel procedures for generating and loading liposomal systems
EP0393145A1 (en) Spontaneous vesiculation of multilamellar liposomes
EP1115382B1 (en) Immunogenic liposome compositions
JPWO2023069498A5 (https=)
CA1334165C (en) Affinity associated vaccine
WO2016103273A1 (en) A dna vaccine formulation in cationic liposome vehicle useful for maximizing vaccine potency for leishmaniasis
Borkar et al. A Concise Review of Liposomal Vaccine Tailoring Methods for Enhancing Vaccination Efficacy
HK1039064B (en) Immunogenic liposome compositions